Double-blind randomized study comparing brand-name and generic phenytoin monotherapy.

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Neurology

Background:

• Phenytoin (PHT) is a widely used antiepileptic drug for seizure prophylaxis.
• Ensuring therapeutic equivalence between brand-name and generic PHT formulations is crucial for patient care.
• Understanding potential pharmacokinetic differences is essential for safe and effective epilepsy management.

Purpose of the Study:

• To compare the serum concentrations and adverse effects of brand-name and generic phenytoin (PHT) in patients with epilepsy.
• To investigate potential pharmacokinetic differences between PHT formulations.
• To assess the clinical implications of using generic versus brand-name PHT.

Main Methods:

• A randomized, double-blind, crossover study design was employed.
• Ten patients on stable phenytoin monotherapy participated.
• Trough serum PHT concentrations and adverse effects were monitored over 3-month periods for each formulation.

Main Results:

• Generic PHT resulted in significantly higher average predose total and free PHT concentrations compared to brand-name PHT (p < 0.005).
• The potency of the generic PHT capsules (104.6%) was higher than the brand-name (99.2%).
• Observed differences in PHT plasma concentrations correlated with the reported differences in capsule potency, consistent with Michaelis-Menten kinetics.

Conclusions:

• Generic phenytoin formulations may lead to increased serum concentrations compared to brand-name products.
• The observed increase in PHT levels with generic use is attributable to differences in capsule potency.
• Clinicians should be aware of potential pharmacokinetic variations between generic and brand-name phenytoin to ensure optimal seizure control and minimize adverse events.